Intas Pharmaceuticals

{{Short description|Indian multinational pharmaceutical company}} {{Use dmy dates|date=October 2021}} {{Use Indian English|date=October 2021}} {{Infobox company | name = Intas Pharmaceuticals | logo = | logo_caption = Expressions for a healthy life | image = Intas Biopharmaceuticals Limited.jpg | image_caption = Headquarters of Intas Biopharmaceuticals (IBPL) | type = Private | founded = {{Start date and age|1977}} | founder = Hasmukh Chudgar | key_people = Binish Chudgar {{small|(Vice Chairman and Joint MD)}} Nimish Chudgar {{small|(Joint MD and CEO)}} Urmish Chudgar {{small|(Joint MD)}} | location = Ahmedabad, Gujarat | hq_location_country = India | industry = Pharmaceuticals Biopharmaceuticals | area_served = Worldwide | products = Pharmaceutical drugs, generic drugs, antiviral drugs, over-the-counter drugs, vaccines, | revenue = {{down}} {{INRConvert|19667|c}} (FY24)<ref name="Revenue"/> | net_income = {{down}} {{INRConvert|1162|c}} (FY24)<ref name="Revenue">{{cite news |title=Intas Pharmaceuticals Limited |url=https://www.icra.in/Rationale/ShowRationaleReport?Id=132465 |access-date=26 September 2025 |work=ICRA}}</ref> | num_employees = 24000+ | num_employees_year = 2025 | subsidiaries = Accord Healthcare | website = {{URL|https://www.intaspharma.com/}} }} '''Intas Pharmaceuticals Limited''' is an Indian multinational pharmaceutical company headquartered in Ahmedabad.<ref name=dreams>{{Cite news|last1=Dandekar|first1=Vikas|last2=Barman|first2=Arijit|title=Chudgars of Intas: A family that dreams big together|work=The Economic Times|url=https://economictimes.indiatimes.com/news/company/corporate-trends/chudgars-of-intas-a-family-that-dreams-big-together/articleshow/54725284.cms|date=7 October 2016}}</ref> It is a producer of generic therapeutic drugs and engaged in contract clinical research and manufacturing.<ref>{{cite news |last1=Shrivastava |first1=Bhuma |title=Intas Pharma may offload 10% to raise Rs200 cr from market |url=https://www.livemint.com/Companies/gJiOpm4Oh1CrbZkuS0l2IM/Intas-Pharma-may-offload-10-to-raise-Rs200-cr-from-market.html |access-date=9 February 2023 |work=mint |date=29 September 2007 |language=en}}</ref> It has 22 manufacturing plants, 17 in India and the rest in Greece, United Kingdom and Mexico.<ref name="Revenue"/> In the financial year 2019, 69% of the company's revenue came from international markets while 31% came from India.<ref name="fy19">{{cite news |title=Financials – Intas Pharmaceuticals Ltd. |url=https://www.intaspharma.com/financials/ |access-date=1 January 2022 |work=Intas Pharmaceuticals Ltd.}}</ref> Its market presence is in more than 100+ countries.{{Citation needed|date=December 2025}}

==History== [[File:Etilaam 1mg Tablet by Intas Pharmaceuticals.JPG|thumb|Etizolam tablets manufactured by Intas.]] The company was founded by a Jain pharmacist Hasmukh Chudgar in 1977<ref>{{Cite web|title=Hasmukh Chudgar & family|url=https://www.forbes.com/profile/hasmukh-chudgar/|access-date=2021-10-03|website=Forbes|language=en}}</ref> and was incorporated in 1985.<ref name=":0">{{Cite web|last1=Dewan|first1=Shamsher|last2=Shah|first2=Kinjal|last3=Jain|first3=Gaurav|last4=Gupta|first4=Vanshika|date=19 July 2021|title=Intas Pharmaceuticals Limited: Long-term rating upgraded to [ICRA]AA+ (Stable); shortterm rating reaffirmed|url=https://www.icra.in/Rationale/ShowRationaleReport/?Id=104712|access-date=3 October 2021|website=ICRA Limited}}</ref>

In 2013, ChrysCapital acquired 16.14% stake in the company, and in 2015, ChrysCapital subsequently sold 10.13% to Singapore-based Temasek Holdings<ref>{{Cite web|last=Sarkar|first=Pooja|date=2015-07-10|title=Temasek pumps more than Rs4,600 crore into India in Q1|url=https://www.livemint.com/Companies/ZpDUEtOhCmp74zpVsqyqqO/Temasek-pumps-in-more-than-Rs4600-crore-into-India-in-Q1.html|access-date=2021-10-03|website=mint|language=en}}</ref> and in 2017, it further diluted 3.01% stake to Capital International. Though, by May 2020, ChrysCapital bought back Capital International's stake.<ref>{{Cite news|first=Madhav|last=Chanchani|date=2 June 2020|title=ChrysCapital backs Intas again, buys 3%, valuation hits $4.3 billion|url=https://timesofindia.indiatimes.com/business/india-business/chryscapital-backs-intas-again-buys-3-valuation-hits-4-3bn/articleshow/76144201.cms|access-date=2021-10-03|newspaper=The Times of India|language=en}}</ref> Currently, the Chudgar family, owns 83.85% stake in the company, with 10.13% being held by Temasek Holdings, and 6.02% by ChrysCapital.<ref name=":0" />

As of March 2021, the company is operating 19 manufacturing facilities globally - 13 in India, 5 in the UK, and 1 in Mexico.<ref name=":0" /> The company has set up a new manufacturing facility in PHARMEZ (Bavla, near Ahmedabad) with capacity to manufacture and export more than 1 billion solid dosages and 5 million injectables.<ref>{{Cite web|last1=Modi|first1=Krunal|last2=Sharma|first2=Ranjan|date=11 March 2021|title=Analyst Report - Intas Pharmaceuticals Limited, March 11, 2021|url=https://www.careratings.com/upload/CompanyFiles/PR/11032021071654_Intas_Pharmaceuticals_Limited.pdf|access-date=2021-10-03|website=CARE Ratings}}</ref>

== Divisions == === Biologics Unit (formerly, Intas Biopharmaceuticals) === In 2000, an independent biotechnology division of Intas Pharmaceuticals was incorporated as Intas Biopharmaceuticals by Urmish Chudgar, a hematologist. Later in 2012–13, the subsidiary was merged with the parent company Intas Pharmaceuticals Limited.<ref>{{Cite news|first=Chitra|last=Unnithan|date=18 June 2012|title=Intas Pharmaceuticals: Intas Pharma merges group companies, subsidiaries|url=https://timesofindia.indiatimes.com/city/ahmedabad/intas-pharma-merges-group-companies-subsidiaries/articleshow/14226717.cms|access-date=2021-10-03|newspaper=The Times of India|language=en}}</ref> This division is involved in development and manufacturing of biosimilar products based on recombinant DNA and monoclonal antibodies.<ref>{{Cite web|last1=Shetty|first1=Sujay|last2=Vishwakarma|first2=Nisha|title=Global pharma looks to India: Prospects for growth|url=https://www.pwc.com/gx/en/pharma-life-sciences/pdf/global-pharma-looks-to-india-final.pdf|access-date=2021-10-03|publisher=PricewaterhouseCoopers|page=19}}</ref>

The company underwent an EU GMP (Good Manufacturing Practice) audit in December 2006 to seek approval for a clinical trial of its biosimilar Filgrastim in Europe and was certified as EU GMP-compliant in April 2007, becoming the first company in India to receive such certification.<ref>{{Cite news|date=13 June 2007|title=Intas mfg unit gets EU-GMP certification|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/intas-mfg-unit-gets-eu-gmp-certification/articleshow/2118921.cms?from=mdr|access-date=2021-10-03}}</ref> In 2015, the company launched its first biosimilar product, Filgrastim in Europe, to treat patients with advanced HIV infection and immune system disorders such as neutropenia.<ref>{{Cite news|last=Subbu|first=Ramnath|date=2015-02-23|title=Intas Pharma launches biosimilar in Europe|language=en-IN|work=The Hindu|url=https://www.thehindu.com/business/Industry/intas-pharma-launches-biosimilar-in-europe/article6925941.ece|access-date=2021-10-03|issn=0971-751X}}</ref><ref>{{Cite web|date=2015-03-06|title=Intas Pharmaceuticals launches biosimilar in Europe|url=https://www.financialexpress.com/india-news/intas-pharmaceuticals-launches-biosimilar-in-europe-2/50917/|access-date=2021-10-03|website=The Financial Express|language=en-US}}</ref>

Apart from EU GMP certification, the company has approvals from MCC South Africa, Gulf Cooperation Council (GCC), Syria, Yemen, Belarus and several other national health authorities for its manufacturing facility and products.<ref>{{Cite web|date=2015-01-23|title=Intas's Growth Driver : Biopharmaceuticals|url=https://nckpharma.com/intas-growth-driver-biopharmaceuticals/|access-date=2021-10-03|website=NCK Pharma|language=en-US}}</ref>

==Subsidiaries== ===Accord Healthcare=== London-headquartered Accord Healthcare is a fully owned subsidiary of Intas Pharmaceuticals, which deals with large-scale generic pharmaceuticals across Europe and North America markets. It also manages an American R&D unit which is located at Research Triangle Park, Durham. As of 2018, the company has approval for 89 Abbreviated New Drug Applications and is selling 255 dosing presentations.<ref>{{Cite journal|date=9 August 2018|title=Accord Healthcare Inc August 9, 2018|url=https://www.pharmacytimes.com/view/accord-healthcare-inc|access-date=2021-10-03|website=Pharmacy Times|series=Generic Supplement 2018 }}</ref>

== Acquisitions == ===Teva Pharmaceuticals (UK & Ireland) === In 2016, Intas acquired the assets of Teva Pharmaceuticals in the UK and Ireland for US$764 million.<ref>{{Cite news|last1=Dandekar|first1=Vikas|last2=Barman|first2=Arijit|date=2016-10-06|title=Intas buys Teva's UK & Ireland assets for $764 million to break into global top 20 generic players club|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/intas-buys-tevas-uk-ireland-assets-for-764-million-to-break-into-global-top-20-generic-players-club/articleshow/54696609.cms?from=mdr|access-date=2020-05-08}}</ref><ref name=dreams/>

=== Actavis (UK & Ireland) === In 2017, the company's Accord Healthcare announced acquisition of Actavis UK Ltd. and Actavis Ireland Ltd from Teva Pharmaceutical Industries, for an enterprise value of £603 million.<ref>{{Cite web|title=Intas Pharmaceuticals Completes Deal to Acquire Actavis|url=https://www.moneycontrol.com/news/business/companies/intas-pharmaceuticals-completes-deal-to-acquire-actavis-941493.html|access-date=2020-05-08|website=Moneycontrol}}</ref><ref>{{Cite web|title=Intas to acquire UK & Ireland generics businesses from Teva for £603 million|url=https://www.thehindubusinessline.com/companies/intas-to-acquire-uk-amp-ireland-generics-businesses-from-teva-for-603-million/article21712880.ece|access-date=2021-07-04|website=@businessline|date=5 October 2016 |language=en}}</ref> The deal included a portfolio of generic medicines and a manufacturing plant in Barnstaple.<ref>{{Cite web|last=Babla|first=Shraddha|title=Intas Pharma In No Hurry To List, Says MD Binish Chudgar|url=https://www.bloombergquint.com/business/intas-pharma-acquires-tevas-uk-ireland-assets-sees-revenue-from-europe-at-dollar600-million|access-date=2021-10-03|website=BloombergQuint|date=7 October 2016 |language=en}}</ref>

=== Sanofi's Fawdon Plant === In 2018, Intas' subsidiary Accord Healthcare reopened Sanofi's Fawdon plant in the UK for manufacturing generic effervescent medicines. The plant was acquired in 2015 after Sanofi closed the facility.<ref>{{Cite web |title=Intas puts the fizz back into ex-Sanofi plant with generic effervescents |author=Flora Southey |work=Outsourcing-Pharma.com |date=31 January 2018 |url= https://www.outsourcing-pharma.com/Article/2018/01/31/Intas-puts-the-fizz-back-into-ex-Sanofi-plant-with-generic-effervescents}}</ref> This is the fifth manufacturing location for Accord in the country after Harrow, Barnstaple, Haverhill, and Didcot.<ref>{{Cite web|date=2018-01-25|title=500 jobs to be created by Accord Healthcare at its new Fawdon Pharmaceutical Factory|url=https://investnortheastengland.co.uk/news/accord-healthcare-new-fawdon-pharmaceutical-factory/|access-date=2021-10-03|website=Invest North East England|language=en-GB}}</ref>

== Controversies == In December 2020, Intas Pharmaceuticals, along with Mankind Pharma, received show-cause notices for selling an anti-diabetic medicine without obtaining mandatory price approval from the National Pharmaceutical Pricing Authority.<ref>{{Cite news|last=Chandna|first=Himani|date=31 December 2020|title=Mankind Pharma, Intas found selling diabetes drug 'without nod', to get show cause notice|work=ThePrint|url=https://theprint.in/health/mankind-pharma-intas-found-selling-diabetes-drug-without-nod-to-get-show-cause-notice/577101/|access-date=2021-10-03}}</ref>

In December 2022, a U.S. FDA inspection found that Intas's manufacturing plant in Sanand, India, was intentionally falsifying laboratory data and destroying critical quality-control records. Inspectors documented a truckload of shredded test records and multiple instances of manipulated results, raising concerns about the reliability of the potency and purity of drugs released from the facility.<ref>{{Cite web |title=Compliance Record: Intas Pharmaceuticals |website=Food and Drug Administration |url=https://www.fda.gov/media/164602/download}}</ref>

In 2023, testing conducted on behalf of the American military by the independent laboratory Valisure found that generic tacrolimus produced by Intas did not perform as an equivalent substitute for the brand-name version, adding to concerns about quality control at the company.<ref>{{cite news |last1=Edney |first1=Anna |last2=Griffin |first2=Riley |title=The Pentagon Wants to Root Out Shoddy Drugs. The FDA Is In Its Way. |url=https://www.bloomberg.com/news/features/2023-12-05/pentagon-is-skeptical-of-cheap-generic-drugs-approved-by-the-fda?sref=CIpmV6x8 |access-date=5 December 2023 |work=Bloomberg.com |date=5 December 2023 |language=en}}</ref> Another study in 2015 had concluded that tacrolimus produced by Accord did not work as intended, yet it remained on the market.<ref>{{cite news |last1=Rose |first1=Megan |last2=Cenziper |first2=Debbie |title=Fighting for Breath |url=https://www.propublica.org/article/fda-generic-drug-equivalents-tacrolimus |access-date=25 December 2025 |work=ProPublica |date=19 December 2025 |language=en}}</ref>

== References == {{reflist|2}}

== External links == * {{Official website}}

Category:Pharmaceutical industry in Gujarat Category:Pharmaceutical industry in India Category:Pharmaceutical companies of Gujarat Category:Indian brands Category:Pharmaceutical companies of India Category:Biotechnology companies of India Category:Pharmaceutical companies established in 1977 Category:Manufacturing companies based in Ahmedabad Category:1977 establishments in Gujarat